Every poster, paper, trial readout, and planned study since Feb 2024 builds credibility. The new team has been laying the foundation for people to more easily evaluate CytoDyn and its work across many diseases now that the FDA relationship is healthy.
5/9/24 Covid PASC publication
7/23/24 HIV AAV delivery poster
7/23/24 Longterm leronlimab poster
9/24/24 MASH fibrosis reduced, preclinical results
9/26/24 HIV mother to newborn receptor blockade paper
9/30/24 Covid Mild Moderate paper
Additional papers coming in mTNBC, MASH, Covid Severe, HIV
Recent and announced studies in; MASH, Glioblastoma, Alzheimer’s, Colorectal cancer, Inflammation, Chronic Fatigue Syndrome, HIV.
This team is working hard.
(22)
(0)
CytoDyn Inc (CYDY) Stock Research Links
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.